Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HCQ and Azithromycin Prophylaxis for Healthcare Workers
NCT04354597Withdrawn
- Sponsor
- King Hussein Cancer Center
- Start
- May 2020
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of hydroxychloroquine and azithromycin in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by King Hussein Cancer Center. Primary endpoint: Effect of HCQ and AZ in preventing infection with COVID-19 at 4 months. Planned start May 2020; status: withdrawn.
02
Drugs
hydroxychloroquineazithromycin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04354597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04354597.